Stay updated with breaking news from Beth Harler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good day, everyone, and welcome to the IGM Biosciences' Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Today's call is being recorded.
The anti-inflammatory medication Zeposia (ozanimod) is under review in the European Union to treat ulcerative colitis in adults.
Bristol Myers Squibb: EMA Validates Marketing Authorization Application For Zeposia NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) said the European Medicines Agency has validated its Marketing Authorization Application for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis. This confirms the submission is complete and begins the EMA's centralized review process. Mary Beth Harler, head of Immunology and Fibrosis Development, Bristol Myers Squibb, said: 'This validation is an important step toward making Zeposia available to eligible patients in the...